Abstract Number: L01 • ACR Convergence 2024
Targeted Exosite Inhibition of STING Activation of TBK1 Selectively Blocks Type I Interferon and NFκB Responses for Treatment of Autoimmune Diseases
Background/Purpose: The cGAS-TBK1-STING pathway senses nucleic acids for innate immunity. Aberrant activation of the pathway is linked to autoimmune diseases including Systemic and Cutaneous Lupus…Abstract Number: L03 • ACR Convergence 2024
CD9 Expressing T Follicular Helper Cells Are a Highly Functional Subset Expanded in Systemic Lupus Erythematosus
Background/Purpose: Systemic Lupus Erythematosus (SLE) is characterized by the generation of autoantibodies that promote tissue injury. The development of pathogenic autoantibody-secreting B cells in lupus…Abstract Number: L10 • ACR Convergence 2024
Neuroimmune Modulation in Adults with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological or Targeted Synthetic DMARDs: Results at 12 and 24 Weeks from a Randomized, Sham-Controlled, Double-Blind Pivotal Study
Background/Purpose: In this study, we evaluated the safety and efficacy of an implantable, cervical vagus nerve stimulation device for treatment of RA. Methods: This randomized,…Abstract Number: L12 • ACR Convergence 2024
A-319, a CD3 X CD19 T Cell Engager (TCE), for the Treatment of Severe/Refractory SLE: Early Evidence of Rapid Reset of Disease-Specific Autoimmunity
Background/Purpose: CD19 CAR T treatment has demonstrated clinical benefits to patients with severe/refractory systemic lupus erythematosus (SLE), possibly due to resetting autoimmunity. A-319, a highly…Abstract Number: L19 • ACR Convergence 2024
Efficacy and Safety of Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still’s Disease: Results from a Phase 3 Study and a Pooled Analysis of Two Prospective Trials
Background/Purpose: MAS is a life-threatening complication of Still’s disease, characterized by interferon-gamma (IFNg)-driven macrophage activation and systemic hyperinflammation. Emapalumab, an anti-IFNg antibody, binds free and…Abstract Number: 0015 • ACR Convergence 2024
Profiling of B and T Cells in Kidney Biopsies from ANCA-associated Vasculitis Patients with Glomerulonephritis at Single-Cell Resolution
Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a small-vessel autoimmune vasculitis, associated with severe lung and kidney impairment. B cells are crucial in AAV…Abstract Number: 0146 • ACR Convergence 2024
Enhancing Pre-Biologic Response Modifier Screening for Coccidioidomycosis in Endemic Regions
Background/Purpose: Biologic response modifiers (BRMs), also known as "biologics," have become essential tools in treating various chronic inflammatory conditions. However, the immunosuppression caused by these agents…Abstract Number: 0293 • ACR Convergence 2024
Assessment of Skin Cancer Risk in Autoimmune Diseases: A Multivariate Analysis Using a National Inpatient Database
Background/Purpose: Autoimmune diseases are known to be associated with an increased risk of many types of cancers. This study investigates the association between different types…Abstract Number: 0379 • ACR Convergence 2024
Effectiveness and Safety of Baricitinib for the Treatment of Juvenile Idiopathic Arthritis Associated Uveitis or Chronic Anterior Antinuclear Antibody Positive Uveitis in Children
Background/Purpose: Baricitinib could target multiple cytokine pathways associated with juvenile idiopathic arthritis associated uveitis (JIA-U) and antinuclear antibody (ANA)-positive uveitis, providing a novel therapeutic approach.…Abstract Number: 0607 • ACR Convergence 2024
Plasma Proteomic Analysis Reveals Type I Interferon Blockade Effects of Anifrolumab in Lupus Nephritis: Insights from a Phase 2 Trial
Background/Purpose: An elevated type I interferon gene signature (IFNGS) is associated with more active disease in patients with LN.1 Anifrolumab, a type I interferon receptor…Abstract Number: 0780 • ACR Convergence 2024
Deep B Cell Tissue Depletion Following Anti-CD19 CART Cells Therapy
Background/Purpose: CD19-targeting chimeric antigen receptor (CAR) T-cell therapy has proved potential for achieving long-term drug-free remission in patients with autoimmune diseases (AIDs). Its effectiveness likely…Abstract Number: 0889 • ACR Convergence 2024
Unraveling the Progression of Sjögren’s Disease at the Cellular and Histological Level Using Single-cell and Spatial Transcriptomics
Background/Purpose: Sjögren’s Disease (SjD) is a systemic autoimmune disease that primarily targets salivary and lacrimal glands, causing tissue deterioration and loss of function. Disease progression…Abstract Number: 0967 • ACR Convergence 2024
Transcriptional Heterogeneity of Immune Cells in the Esophagus of Systemic Sclerosis Patients: A Comparison of Upper and Lower Esophageal Regions
Background/Purpose: Systemic sclerosis (SSc) is characterized by an initial inflammatory phase followed by fibrosis. Esophageal dysfunction in SSc is associated with gastroesophageal reflux, leading to…Abstract Number: 1121 • ACR Convergence 2024
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of AMG 329, a Monoclonal Antibody, in Conventional and Plasmacytoid Dendritic Cell-Mediated Rheumatic Diseases
Background/Purpose: AMG 329 (formerly HZN-1116), a human monoclonal antibody (mAb), binds to soluble and membrane-bound human feline McDonough sarcoma (FMS)-like tyrosine kinase 3 receptor ligand…Abstract Number: 1406 • ACR Convergence 2024
Development and Functional Characterization of Salivary Gland Organoids to Investigate Sjögren’s Disease
Background/Purpose: Sjögren’s disease (SjD) is a systemic autoimmune disease that manifests as glandular dryness and systemic symptoms. Salivary gland epithelial cells (SGEC) are pivotal in…
- 1
- 2
- 3
- …
- 80
- Next Page »